Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia

by Viprakasit V.
Published 2023

Iron chelation therapy in the management of thalassemia: The Asian perspectives

by Viprakasit, V., Lee-Lee, C., Chong, Q.T., Lin, K.-H., Khuhapinant, A.
Published 2016

Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escala...

by Viprakasit V., Nuchprayoon I., Chuansumrit A., Torcharus K., Pongtanakul B., Laothamatas J., Srichairatanakool S., Pooliam J., Supajitkasem S., Suriyaphol P., Tanphaichitr V.S., Tuchinda S.
Published 2014

Deferiprone (GPO-L-ONE?) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escala...

by Viprakasit V., Nuchprayoon I., Chuansumrit A., Torcharus K., Pongtanakul B., Laothamatas J., Srichairatanakool S., Pooliam J., Supajitkasem S., Suriyaphol P., Tanphaichitr V.S., Tuchinda S.
Published 2014

Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial sider...

by Pennell, D., Porter, J., Cappellini, M., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M., Kattamis, A., Smith, G., Habr, D., Roubert, B., Taher, A.
Published 2010

Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone t...

by Pennell, D., Porter, J., Cappellini, M., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M., Kattamis, A., Smith, G., Habr, D., Roubert, B., Taher, A.
Published 2010

Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years

by Pennell, D., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, Chi-Kong, Viprakasit, V., Elalfy, M.S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A.
Published 2010

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia

by Pennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Sutcharitchan, P., Li, C.K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A.
Published 2010

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

by Cappellini, M.D., Porter, J., El-Beshlawy, A., Li, C.K., Seymour, J.F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J.W., Chan, L.L., Lin, K.H., Rose, C., Taher, A., Thein, S.L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Investigators, EPIC Study
Published 2010

A phase 3 trial of Luspatercept in patients with transfusion-dependent beta-thalassemia

by Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H. -K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., Chew, L. -P., Bee, P. -C., Lim, S. -M., Lu, M. -Y., Tantiworawit, A., Ganeva, P., Gercheva, L., Shah, F., Neufeld, E. J., Thompson, A., Laadem, A., Shetty, J. K., Zou, J., Zhang, J., Miteva, D., Zinger, T., Linde, P. G., Sherman, M. L., Hermine, O., Porter, J., Piga, A., Investigators, BELIEVE
Published 2020

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

by Gattermann,N., Finelli,C., Della Porta,M., Fénaux,P., Ganser,A.G., Guerci-Bresler,A., Schmid,M.L., Taylor,K.M., Vassilieff,D., Habr,D., Domokos,G., Roubert,B., Rose,C.S., Aǧaoǧlu,L., Alimena,G., Alonso,D., Amé,S., Angelucci,E., Arrizabalaga,B., Athanasiou-Metaxa,M., Augustson,B.M., Aydınok,Y., Baba,A.A., Baccarani,M., Beck,J.T., Béris,P.H., Beyne-Rauzy,O., Birgens,H.S., B́ordessoule,D., Borgna-Pignatti,C., Bosly,A.E., Bouabdallah,K., Bowden,D.K., Bowen,D.T., Bron,D.G., Cappellini,M.D.O., Capra,M.E.Z., Cartron,G., Cazzola,M., Chalkias,C., Chan,L., Chancharunee,S., Chapman,C.S., Charoenkwan,P., Chasapopoulou,E., Chèze,S., Chuansumrit,A., Cianciulli,P., Dauriac,C., Delforge,M., Dölken,G., Dombret,H., Duyster,J., Economopoulos,T.H., Ehninger,G.E., Elalfy,M.S., El Beshlawy,A., Enggaard,L., Fillet,G., Filosa,A., Forni,G.L., Galanello,R., Gastl,G.A., Giraudier,S., Goldfarb,A.W., Grigg,A.P., Gümrük,F.U., Ha,S.Y., Haase,D., Heinrich,B., Hertzberg,M.S., Ho,J., Hsu,H., Huang,S., Hunault-Berger,M., Inusa,B.P.D., Jaulmes,D., Jensen,J.M., Kattamis,A.C., Kilinç,Y., Kim,K., Kinsey,S.E., Kjeldsen,L., Koren,A., Lai,M., Lai,Y., Lee,J., Lee,K., Lee,S., Legros,L., Li,C., Li,C., Li,Q., Lin,K., Linkesch,W.M., Lübbert,M., Lutz,D., Mohamed Thalha,A.J., Mufti,G.J., Muus,P.K., Nobile,F., Papadopoulos,N.T., Perrotta,S., Petrini,M.T., Pfeilstöcker,M., Piga,A.M., Poole,J.E., Porter,J.B., Pungolino,E.M., Quarta,G., Ravoet,C., Jolimont Lobbes,H.H., Remacha,A.F., Roy,L., Saglio,G.G., Sanz,G.F., Schmugge,M., Schots,H., Secchi,G., Seymour,J.F., Shah,F.T., Shah,H.N., Shen,Z., Slama,B., Sutcharitchan,P., Taher,A.T., Tamary,H., Tesch,H.J., Thein,S.L., Troncy,J., Villegas,A.M., Viprakasit,V., Wainwright,L., Waßmann,B., Wettervald,M., Will,A.M., Wörmann,B.J., Wright,J.G., Yeh,S., Yoon,S., Zoumbos,N.C., Zweegman,S.
Published 2015